** Shares of drugmaker BridgeBio Pharma BBIO.O rise 2.7% to $39.67
** Brokerage H.C. Wainwright raises PT to $56 from $53
** Believe BBIO's rare heart disease drug, acoramidis, could reach annualized revenue run rate of more than $1 billion in mid- to late 2027 in the U.S. — H.C. Wainwright
** Acoramidis reduced incidence of atrial fibrillation events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), BBIO said in May
** Believe that this evidence, coupled with the growing proof that increased TTR stabilization extent is closely linked to favorable outcomes, should accelerate acoramidis market adoption — brokerage
** BBIO has fallen 8.3% YTD, as of last close
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。